In vitro properties of recombinant anti-CD20 mAbs
| Type I mAbs (rituximab, ofatumumab, veltuzumab, ublituximab, ocaratuzumab, ocrelizumab, PRO131921) . | Type II mAbs (obinutuzumab) . |
|---|---|
| Translocate CD20 into lipid rafts→ CDC | Do not translocate CD20 into lipid rafts→ No CDC |
| No homotypic adhesion | Homotypic adhesion |
| Caspase-dependent cell death | Lysosome-dependent cell death |
| CD20 modulation | No CD20 modulation |
| ADCC | |
| ADCP | |
| Type I mAbs (rituximab, ofatumumab, veltuzumab, ublituximab, ocaratuzumab, ocrelizumab, PRO131921) . | Type II mAbs (obinutuzumab) . |
|---|---|
| Translocate CD20 into lipid rafts→ CDC | Do not translocate CD20 into lipid rafts→ No CDC |
| No homotypic adhesion | Homotypic adhesion |
| Caspase-dependent cell death | Lysosome-dependent cell death |
| CD20 modulation | No CD20 modulation |
| ADCC | |
| ADCP | |